NASDAQ:PYPD PolyPid (PYPD) Stock Price, News & Analysis $3.46 -0.04 (-1.14%) (As of 07/26/2024 ET) Add Compare Share Share Today's Range$3.46▼$3.4650-Day Range$3.43▼$4.7152-Week Range$3.38▼$12.00Volume390 shsAverage Volume6,152 shsMarket Capitalization$16.61 millionP/E RatioN/ADividend YieldN/APrice Target$14.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOwnershipSEC FilingsShort InterestTrends Get PolyPid alerts: Email Address PolyPid MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside304.6% Upside$14.00 Price TargetShort InterestHealthy0.30% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.96Based on 3 Articles This WeekInsider TradingN/AProj. Earnings GrowthGrowingFrom ($4.98) to ($2.56) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.3.18 out of 5 starsMedical Sector370th out of 936 stocksSurgical & Medical Instruments Industry45th out of 101 stocks 3.5 Analyst's Opinion Consensus RatingPolyPid has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.Amount of Analyst CoveragePolyPid has only been the subject of 1 research reports in the past 90 days.Read more about PolyPid's stock forecast and price target. Previous Next 5.0 Short Interest Percentage of Shares Shorted0.30% of the float of PolyPid has been sold short.Short Interest Ratio / Days to CoverPolyPid has a short interest ratio ("days to cover") of 0.6, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in PolyPid has recently decreased by 46.00%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldPolyPid does not currently pay a dividend.Dividend GrowthPolyPid does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for PYPD. Previous Next 2.8 News and Social Media Coverage News SentimentPolyPid has a news sentiment score of 0.96. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.61 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 3 news articles for PolyPid this week, compared to 1 article on an average week. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, PolyPid insiders have not sold or bought any company stock.Percentage Held by Insiders24.70% of the stock of PolyPid is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsOnly 26.47% of the stock of PolyPid is held by institutions.Read more about PolyPid's insider trading history. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for PolyPid are expected to grow in the coming year, from ($4.98) to ($2.56) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of PolyPid is -0.27, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of PolyPid is -0.27, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Read more about PolyPid's valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Porter & CompanyMy grim warning about AI stocksToday, I’m warning of another looming catastrophe. Only this time, it’s not in pot stocks, cryptos, or U.S. housing… it's in artificial intelligence. And unless you know what’s really going on in this sector, you could be wiped out. You see, while there is no doubt that the recent advancements in artificial intelligence are game-changing and will drive colossal innovation in every sector of the economy... There's also no escaping that The Big AI Die-Up is coming.So go here now to read my new report The Big AI Die-Up… while you still can. About PolyPid Stock (NASDAQ:PYPD)PolyPid Ltd., a clinical-stage biopharmaceutical company, developing targeted, locally administered, and prolonged-release therapeutics using its proprietary polymer-lipid encapsulation matrix (PLEX) technology to address unmet medical needs. Its lead product candidate is D-PLEX100, which is in a pivotal Phase 3 confirmatory trial for prevention of surgical site infections (SSIs) in patients undergoing abdominal colorectal surgery with large incisions. It is also developing OncoPLEX, for the treatment of intra-tumoral cancer. PolyPid Ltd. was incorporated in 2008 and is headquartered in Petah Tikva, Israel.Read More PYPD Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart PYPD Stock News HeadlinesJuly 24 at 3:54 AM | americanbankingnews.comPolyPid (NASDAQ:PYPD) Stock Price Up 1.7%June 10, 2024 | globenewswire.comPolyPid to Host Virtual KOL Event on June 17, 2024, and Provide an Update on the Company's Ongoing D-PLEX₁₀₀ Phase 3 TrialJuly 27, 2024 | Porter & Company (Ad)My grim warning about AI stocksToday, I’m warning of another looming catastrophe. Only this time, it’s not in pot stocks, cryptos, or U.S. housing… it's in artificial intelligence. And unless you know what’s really going on in this sector, you could be wiped out. You see, while there is no doubt that the recent advancements in artificial intelligence are game-changing and will drive colossal innovation in every sector of the economy... There's also no escaping that The Big AI Die-Up is coming.May 12, 2024 | investing.comEarnings call: PolyPid reports progress in D-PLEX100 trial, eyes expansionMay 10, 2024 | finance.yahoo.comPolyPid Ltd. (NASDAQ:PYPD) Q1 2024 Earnings Call TranscriptMay 9, 2024 | markets.businessinsider.comBuy Rating Affirmed for PolyPid on D-PLEX Progress and Solid Financial FootingMay 8, 2024 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: PolyPid (PYPD) and Cartesian Therapeutics (RNAC)May 8, 2024 | investorplace.comPYPD Stock Earnings: PolyPid Beats EPS for Q1 2024July 27, 2024 | Porter & Company (Ad)My grim warning about AI stocksToday, I’m warning of another looming catastrophe. Only this time, it’s not in pot stocks, cryptos, or U.S. housing… it's in artificial intelligence. And unless you know what’s really going on in this sector, you could be wiped out. You see, while there is no doubt that the recent advancements in artificial intelligence are game-changing and will drive colossal innovation in every sector of the economy... There's also no escaping that The Big AI Die-Up is coming.May 8, 2024 | globenewswire.comPolyPid Provides Corporate Update and Reports First Quarter 2024 Financial ResultsMay 1, 2024 | globenewswire.comPolyPid to Participate in Citizens JMP Life Sciences ConferenceApril 30, 2024 | markets.businessinsider.comBuy Rating Affirmed for PolyPid on Strong Trial Progress and Expanding Pipeline PotentialApril 30, 2024 | globenewswire.comPolyPid Announces Enrollment of 200th Patient in Ongoing SHIELD II Phase 3 Trial Evaluating D-PLEX₁₀₀ for the Prevention of Abdominal Colorectal Surgical Site InfectionsApril 24, 2024 | msn.comPYPD: Polypid is Enhancing Surgical OutcomesApril 24, 2024 | globenewswire.comPolyPid to Report First Quarter 2024 Financial Results and Operational Highlights on May 8, 2024April 18, 2024 | finance.yahoo.comPolyPid Ltd. (PYPD) Stock Historical Prices & Data - Yahoo FinanceFebruary 28, 2024 | globenewswire.comPolyPid to Participate in Barclays 26th Annual Global Healthcare ConferenceFebruary 19, 2024 | finance.yahoo.comPolyPid Ltd. (PYPD) Upgraded to Buy: What Does It Mean for the Stock?See More Headlines Receive PYPD Stock News and Ratings via Email Sign-up to receive the latest news and ratings for PolyPid and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/08/2024Today7/26/2024Next Earnings (Estimated)8/14/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Surgical & medical instruments Sub-IndustryN/A Current SymbolNASDAQ:PYPD CUSIPN/A CIK1611842 Webwww.polypid.com Phone972-74-719-5700FaxN/AEmployees59Year FoundedN/APrice Target and Rating Average Stock Price Target$14.00 High Stock Price Target$14.00 Low Stock Price Target$14.00 Potential Upside/Downside+304.6%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage1 Analysts Profitability EPS (Most Recent Fiscal Year)($12.6439) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-23,860,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-572.69% Return on Assets-110.25% Debt Debt-to-Equity Ratio0.60 Current Ratio1.64 Quick Ratio1.64 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value($1.27) per share Price / Book-2.72Miscellaneous Outstanding Shares4,800,000Free Float3,612,000Market Cap$16.61 million OptionableNo Data Beta1.31 The 10 Best AI Stocks to Own in 2024Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.Get This Free Report Key ExecutivesMs. Dikla Czaczkes Akselbrad (Age 51)CEO & Director Comp: $347.88kMr. Jonny Missulawin (Age 37)Chief Financial Officer Comp: $186.96kMs. Dalit Hazan (Age 53)Executive Vice President of R&D and Clinical & Regulatory Affairs Comp: $272.38kMr. Ori Warshavsky (Age 46)Chief Operating Officer - US Comp: $340.89kMs. Maria RubinVice President of OperationsMr. Tal VilnaiGeneral Counsel & Corporate SecretaryMs. Rivi Lev-ariVice President of Human ResourceDr. Jean-Marc Hagai Pharm.D.Chief Commercial OfficerMore ExecutivesKey CompetitorsPro-DexNASDAQ:PDEXInspireMDNYSE:NSPRLENSARNASDAQ:LNSRSEP AcquisitionNASDAQ:SEPANeuroneticsNASDAQ:STIMView All Competitors PYPD Stock Analysis - Frequently Asked Questions How have PYPD shares performed this year? PolyPid's stock was trading at $3.80 at the start of the year. Since then, PYPD stock has decreased by 8.9% and is now trading at $3.46. View the best growth stocks for 2024 here. How were PolyPid's earnings last quarter? PolyPid Ltd. (NASDAQ:PYPD) issued its quarterly earnings data on Wednesday, May, 8th. The company reported ($1.37) EPS for the quarter, topping the consensus estimate of ($1.96) by $0.59. When did PolyPid's stock split? Shares of PolyPid reverse split on Thursday, September 21st 2023. The 1-30 reverse split was announced on Wednesday, September 20th 2023. The number of shares owned by shareholders was adjusted after the closing bell on Wednesday, September 20th 2023. An investor that had 100 shares of stock prior to the reverse split would have 3 shares after the split. When did PolyPid IPO? PolyPid (PYPD) raised $50 million in an initial public offering on Friday, June 26th 2020. The company issued 3,100,000 shares at a price of $15.00-$17.00 per share. Barclays and BMO Capital Markets acted as the underwriters for the IPO and Raymond James, National Securities Corporation, Oddo BHF and A.G.P. were co-managers. How do I buy shares of PolyPid? Shares of PYPD stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of PolyPid own? Based on aggregate information from My MarketBeat watchlists, some other companies that PolyPid investors own include Advanced Micro Devices (AMD), Moderna (MRNA), Sorrento Therapeutics (SRNE), Trevena (TRVN), Cardinal Health (CAH) and Genocea Biosciences (GNCA). This page (NASDAQ:PYPD) was last updated on 7/27/2024 by MarketBeat.com Staff From Our Partners625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | Sponsored“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 sp...Unstoppable Prosperity | SponsoredNext opportunity for crypto millionsThe Bitcoin halving is the #1 creator of "crypto millionaires". That's because historically, every halving has...Crypto 101 Media | Sponsoredtop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)AI was by far the biggest tech investing trend right now. But Ross Givens says the #1 artificial intelligen...Traders Agency | SponsoredThe #1 Crypto for 2024 (3 Cent Coin)Chris Rowe – the man who recommended Amazon in 1998… Bitcoin and Ethereum in 2017… And has spotted 44 diffe...True Market Insiders | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | SponsoredDon't Pay a Dime for Marc Lichtenfeld's Top AI PicksUsually, you'd have to plunk down a hefty sum to get your hands on Marc Lichtenfeld's latest income research.....The Oxford Club | SponsoredNEW AI developed by trader who won 1,129% (in 2 days)Earlier this year one legendary trader captured a 1,129% win (in just 2 days) ... LIVE in front of thousands o...Monument Traders Alliance | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding PolyPid Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. Share PolyPid With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
